Sun Li Na

2009 8 2014 8 2014 9 2020 8 2020 9 1 2016 、 、 2018 2 2018 2019 2019 、 、 2020 2020 2022 2022 2023 (1)Sun L, Chen Y. Interpretation of the Key Issues of Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease. J TranslInt Med. 2023 Jan 13;10(4):277-280.doi: 10.2478/jtim-2022-0069. PMID: 36860626;PMCID: PMC9969563. (2)Feng J#,, Sun L#, Sun X, Xu L, Liu L, Liu G, Wang J, Gao P, Zhan S, Chen Y, WangS, Sun Y. Increasing prevalence and burden of bronchiectasis in urban Chineseadults, 2013-2017: a nationwide population-based cohort study. Respir Res. 2022 May 4;23(1):111. doi: 10.1186/s12931-022-02023-8. (3)Ding Y#, Sun L#, Wang Y, Zhang J, Chen Y. Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials.Int J Chron Obstruct Pulmon Dis.2022 May 5;17:1051-1067. (4)Guo C#, Sun L#, Zhang L, Dong F, Zhang X, Yao L*, Chang C*. Serum sphingolipid profile in asthma. J Leukoc Biol. 2021 Jul;110(1):53-59. (5) Jie Xia #, Lina Sun #, Suqin Xu, Qiu Xiang, Jianping Zhao, Weining Xiong, Yongjian Xu, Shuyuan Chu. A Model Using Support Vector Machines Recursive Feature Elimination (SVM-RFE) Algorithm to Classify Whether COPD Patients Have Been Continuously Managed According to GOLD Guidelines. Int J Chron Obstruct Pulmon Dis. 2020 Nov 4;15:2779-2786. (6)Sun L#, Chen Y#, Wu R, Lu M, Yao W*. Changes in definition lead to changes in the clinical characteristics across COPD categories according to GOLD 2017: a national cross-sectional survey in China. Int J Chron Obstruct Pulmon Dis,2017,12: 3095–3102. (7), *,,..,2016,16(6):716-721. (8),,,,,,,,,,,,,,,, *..,2015,95(8):570-576. (9), *,,,..,2014, 46 (4): 662-667. (10), *... 2014, 34(8): 808-810. (11), *...2010.30( 17):1054-1057.